Guidance on the use and side effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), their safety, use in pregnancy and the risk of suicidal behaviour.
The Medicines and Healthcare Products Regulatory Agency (MHRA) guidance for healthcare professionals covers:
- risk of suicidal behaviour
- withdrawal reactions
- use in pregnancy
- effects on tamoxifen effectiveness
- interaction with methylthioninium chloride